# **Data Fitness Findings Report**

## IND27034

BioNTech SE and Pfizer, April 2021

Findings			Notes
C4591001 EUA Amendment (12-15 Years of Age)			
Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-			
19 in Healthy Individuals.			
Document / Standard	Version	Notes	
annotated CRF		Seems fine	
SDTM Implementation Guide	SDTM-IG v3.2		
SDTM Controlled Terminology	2020-03-27		
SDTM define.xml	V2.0	Seems fine	
Medications Dictionary	WHODD GLOBALV3Mar20, WHO DDE v202003		
Medical Events Dictionary (MedDRA)	V23.1		
SDTM Reviewer's Guide		Seems fine	

#### Data Issues

#### Adverse event marked as AEREL = RELATED, but subject didn't receive dose yet

- USUBJID = C4591001 1226 12261520, AETERM = Pain at injection site, AESTDTC = 2020-09-02T21:00
  - 2 EX records: EXSTDTC = 2020-09-03T15:06:00 and 2020-09-22T10:22:00

#### Subjects have AE records with AEACN = DRUG WITHDRAWN but no ADVERSE EVENT record in DS

• 20 subjects - see report "IND27034 - 12-15 years - AEACN of DRUG WITHDRAWN but no DS ADVERSE EVENT record.xlsx"

### Value for CEHLGT not found in MedDRA dictionary

- 1 record (0%)
- cSDRG explanation: "Manually coded as "Virus infectious disorders"."
- The correct value per the MedDRA dictionary is: Viral infectious disorders

#### Inconsistent coding of MHTERM mhhlt mhhlgt mhbodsys STUDYID count\_of meddrav mhterm mhdecod mhs SKIN CANCER SKIN CANCER SKIN NEOPLASMS SKIN NEOPLASMS NEOPLASMS BENIGN, C4591001 2 23.1 MALIGNANT AND MALIGNANT AND MALIGNANT AND UNSPECIFIED (EXCL UNSPECIFIED UNSPECIFIED (INCL MELANOMA) CYSTS AND POLYPS) SKIN CANCER SKIN NEOPLASM SURGICAL AND MEDICAL 23.1 SKIN LESION SKIN AND C4591001 1 EXCISION EXCISIONS SUBCUTANEOUS PROCEDURES TISSUE THERAPEUTIC PROCEDURES